Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.

被引：1
|
作者：
Garcaa-Donas, Jesas
Roldan, Jose Maria
Lainez, Nuria
Castellano, Daniel E.
Gonzalez, Emilio Esteban
Climent, Miguel A.
Puente, Javier
Francisco Rodriguez-Moreno, Juan
Alonso Gordoa, Teresa
Gonzalez del Alba, Aranzazu
Angel Arranz, Jose
Santos, Maria
Hernando Polo, Susana
Domenech, Montserrat
Rodriguez, Laura
Herrador, Alejandro
Isabel Saez, M.
Gallardo Diaz, Enrique
Maria Gutierrez, Ana
Rodriguez-Antona, Cristina
机构：
[1] Fdn Hosp Madrid, Madrid, Spain
[2] Spanish Camcer Res Ctr, Madrid, Spain
[3] Complejo Hosp Navarra, Pamplona, Spain
[4] Hosp 12 Octubre, Madrid, Spain
[5] Hosp Univ Cent Asturias, Oviedo, Spain
[6] Fdn Inst Valenciano Oncol, Valencia, Spain
[7] Hosp Univ Clin San Carlos, Madrid, Spain
[8] Hosp Univ HM Sanchinarro, Madrid, Spain
[9] Hosp Univ Ramon y Cajal, Madrid, Spain
[10] Son Espases Univ Hosp, Palma De Mallorca, Spain
[11] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[12] Spanish Natl Canc Res Ctr, Madrid, Spain
[13] Hosp Univ Fdn Alcorcon, Alcorcon, Spain
[14] Hosp Althaia, Manresa, Spain
[15] Hosp Univ Fuenlabrada, Fuenlabrada, Spain
[16] Clara Campal Comprehens Canc Ctr CIOCC, Madrid, Spain
[17] Hosp Univ Virgen de la Victoria & Reg Malaga, CNIO IBIMA Genitourinary Canc Res Unit, CRIS Canc Fdn Prostate Canc Res Grp, Inst Biomed Res Malaga, Malaga, Spain
[18] Univ Autonoma Barcelona, Parc Tauli Sabadell Hosp Univ, Inst Invest Innovacio Parc Tauli, Dept Oncol, Sabadell, Spain
[19] Hosp Puerta Sur, Mostoles, Spain
[20] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4559
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors.
    de Kouchkovsky, Ivan
    Zhang Li
    Philip, Errol
    Wright, Francis
    Kim, Daniel Myung
    Natesan, Divya
    Kwon, Daniel
    Ho, Hansen
    Ho, Son
    Chan, Emily
    Porten, Sima P.
    Desai, Arpita
    Huang, Franklin W.
    Chou, Jonathan
    Oh, David Yoonsuk
    Pruthi, Raj
    Fong, Lawrence
    Small, Eric Jay
    Friedlander, Terence W.
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [22] THE EFFECTAND TOLERABILITY OF MTOR INHIBITORS FOR METASTATIC RENAL CELL CARCINOMA
    Tamada, S.
    Iguchi, T.
    Kawashima, H.
    Nakatani, T.
    ANNALS OF ONCOLOGY, 2013, 24 : 89 - 89
  • [23] mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma
    Ravaud, A.
    Bernhard, J. -C.
    Gross-Goupil, M.
    Digue, L.
    Ferriere, J. -M.
    BULLETIN DU CANCER, 2010, 97 : S45 - S51
  • [24] Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
    Shao, Ning
    Wan, Fangning
    Zhu, Yao
    Ye, Dingwei
    MEDICAL SCIENCE MONITOR, 2019, 25 : 6518 - 6522
  • [25] ELDERLY PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) SUCCESSFULLY TREATED
    Bracarda, S.
    Procopio, G.
    Keilholz, U.
    Negrier, S. G.
    Szczylik, C.
    Beck, J.
    Strauss, U. P.
    Burock, K.
    Mersmann, S.
    Escudier, B.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 156 - 156
  • [26] Relative risk of hematological toxicities in patients with advanced renal cell carcinoma treated with upfront immune checkpoint inhibitors
    Jahan, Nusrat
    Ball, Somedeb
    Quirch, Miguel
    Rehman, Shabnam
    Thein, Kyaw Zin
    Tijani, Lukman Aderoju
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [27] Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
    Cho, Daniel C.
    ONCOTARGETS AND THERAPY, 2013, 6 : 679 - 684
  • [28] Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy
    Maj-Hes, Agnes
    Medioni, Jacques
    Scotte, Florian
    Schmidinger, Manuela
    Kramer, Gero
    Combe, Pierre
    Gornadha, Yohan
    Elaidi, Reza
    Oudard, Stephane
    ONCOLOGY, 2013, 85 (01) : 8 - 13
  • [29] Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma
    Husseinzadeh, Holleh D.
    Garcia, Jorge A.
    CURRENT CLINICAL PHARMACOLOGY, 2011, 6 (03): : 214 - 221
  • [30] Clear Cell Papillary Renal Cell Carcinoma: Clinicopathologic, Immunohistochemical, and Molecular Analysis.
    Duan, L.
    Youssef, R. F.
    Margulis, V.
    Lotan, Y.
    Koduru, P.
    Kabbani, W.
    Kapur, P.
    MODERN PATHOLOGY, 2011, 24 : 189A - 189A
12345